Pharmacy school earns CHEA award
EDWARDSVILLE, Ill. — A pharmacy school in Illinois is the first of its kind to win 1-of-4 national 2011 Council for Higher Education Accreditation Awards.
The CHEA gave the award to the Southern Illinois University Edwardsville School of Pharmacy. The award recognizes schools that the CHEA considers exceptional in developing and applying evidence of student-learning outcomes to improve higher education quality and accountability.
The SIUE school’s application focused on a mandatory senior capstone project in which students must create a business plan related to a specific aspect of pharmacy in order to demonstrate the knowledge they have gained.
“CHEA is pleased to acknowledge the work of Southern Illinois University Edwardsville School of Pharmacy in providing an example of institutional progress and effective approaches to use the student-learning outcomes,” CHEA president Judith Eaton said.
J&J posts losses for Q4, full-year earnings
NEW BRUNSWICK, N.J. — Johnson & Johnson posted decreases in sales for fourth quarter 2010 and for the year, according to an earnings statement released Tuesday.
Sales for the quarter were $15.6 billion, a 5.5% decrease from fourth quarter 2009’s $16.5 billion. Sales for the year were $61.6 billion, down by 0.5% from $61.9 billion in 2009.
Meanwhile, profits for the quarter were $1.9 billion, a 12% decrease from $2.2 billion in fourth quarter 2009. Profits for the year were $13.3 billion, an 8.7% increase over $12.3 billion in 2009.
In the pharmaceutical segment, generic competition and other factors decreased sales for most of the company’s major products, but the HIV drug Prezista (darunavir) had sales of $401 million for the year, compared with $303 million in 2009. The new, extended-release schizophrenia drug Invega (paliperidone) had sales of $270 million, compared with $266 million in 2009. The pharmaceutical segment as a whole had sales of $12.5 billion for the year, a 4% decrease from $13 billion in 2009.
Eisai’s severe sepsis drug fails in trial
WOODCLIFF LAKE, N.J. — Eisai will not seek regulatory approval for a drug to treat severe sepsis after getting lackluster results from a late-stage clinical trial, the drug maker said Tuesday.
Eisai said a phase-3 trial of the drug eritoran found the drug did not significantly reduce mortality in patients with the condition compared with placebo.
Severe sepsis causes about 215,000 deaths in the United States every year, with a mortality rate of about 30%.
In other news, however, the company said it would file for approval of perampanel, a drug for epilepsy, following more promising results from a phase-3 trial.